Rapid and life-threatening heart failure induced by pazopanib

BMJ Case Rep. 2018 Aug 16:2018:bcr2018225613. doi: 10.1136/bcr-2018-225613.

Abstract

A 70-year-old man with history of stage IV renal cell carcinoma, chronic atrial fibrillation on warfarin, coronary artery disease status post-percutaneous coronary intervention resulting in an ischaemic cardiomyopathy with left ventricular ejection fraction of 40%-45%, presented with shortness of breath 10 days after starting pazopanib. Within the first week of starting pazopanib, the patient developed fatigue and progressive dyspnoea on exertion. His symptoms quickly worsened and he had compromised mental status. He was transferred to the intensive care unit (ICU) and intubated due to continued respiratory distress. He was found to be in cardiogenic shock and was started on inotropic support with dobutamine and norepinephrine. With maximum support, the patient was slowly weaned off vasopressors and was successfully extubated on ICU day 9. His hospital stay lasted 29 days with management of multiple medical complications, and he was eventually discharged to a rehabilitation facility.

Keywords: cancer intervention; heart failure.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents / adverse effects*
  • Carcinoma, Renal Cell / drug therapy*
  • Heart Failure / chemically induced*
  • Humans
  • Indazoles
  • Kidney Neoplasms / drug therapy*
  • Male
  • Pyrimidines / adverse effects*
  • Sulfonamides / adverse effects*

Substances

  • Antineoplastic Agents
  • Indazoles
  • Pyrimidines
  • Sulfonamides
  • pazopanib